Involvement of Globus Pallidus and Midbrain Nuclei in Pantothenate Kinase-associated Neurodegeneration: Measurement of T2 and T2* Time
Overview
Affiliations
Purpose: To quantify involvement of globus pallidus and two midbrain nuclei (substantia nigra and red nucleus) in Pantothenate Kinase-Associated Neurodegeneration (PKAN).
Material And Methods: We performed T2 and T2* weighted imaging with calculation of the corresponding relaxation times on a subset of 5 patients from a larger group of 20 patients with PKAN from the southwest part of the Dominican Republic. Examinations were carried out on a 3T scanner and included a multi-echo spin-echo as well as a multi-echo gradient echo sequence. Results were compared to a control group of 19 volunteers.
Results: T2 and T2* weighted sequences showed abnormal signal reduction in the globus pallidus of all patients. On T2* weighted imaging, abnormal signal in the substantia nigra could reliably be detected in 75% of cases, but differentiation from normal was less reliable in T2 weighted scans. Correspondingly, relaxation times differed from normal with very high significance (p < 0.0001) in the globus pallidus, but with with less significance in the substantia nigra (p ≤ 0.03). The red nucleus was not affected.
Conclusions: Signal reduction in the globus pallidus, which probably is due to abnormal accumulation of iron, is severe in PKAN and can be differentiated from normal with high reliability. The substantia nigra is affected to a lesser degree, and the red nucleus is not involved. The reason for this selective susceptibility of normally iron-rich brain structures for pathological accumulation of iron remains speculative. Our quantitative results might be helpful to assess the value of an iron chelation approach to therapy.
Micek M, Aebisher D, Surowka J, Bartusik-Aebisher D, Madera M Front Oncol. 2022; 12:1010643.
PMID: 36531030 PMC: 9749890. DOI: 10.3389/fonc.2022.1010643.
Cerebral Iron Deposition in Neurodegeneration.
Dusek P, Hofer T, Alexander J, Roos P, Aaseth J Biomolecules. 2022; 12(5).
PMID: 35625641 PMC: 9138489. DOI: 10.3390/biom12050714.
Dusek P, Tovar Martinez E, Madai V, Jech R, Sobesky J, Paul F Mov Disord Clin Pract. 2018; 1(4):329-335.
PMID: 30363918 PMC: 6183259. DOI: 10.1002/mdc3.12080.
New Perspectives in Iron Chelation Therapy for the Treatment of Neurodegenerative Diseases.
Nunez M, Chana-Cuevas P Pharmaceuticals (Basel). 2018; 11(4).
PMID: 30347635 PMC: 6316457. DOI: 10.3390/ph11040109.
Al Macki N, Al Rashdi I Oman Med J. 2017; 32(1):66-68.
PMID: 28042406 PMC: 5187394. DOI: 10.5001/omj.2017.12.